Schering-Plough Lays Out Phase III Plan For HCV Therapy Boceprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Surprise move pre-dates final Phase II SPRINT-1 data, closes gap with Vertex’s telaprevir.
You may also be interested in...
Length Of Therapy Becomes An Issue In HCV Protease Inhibitor Race
Schering-Plough’s Phase II boceprevir data are likely to fuel the debate.
Length Of Therapy Becomes An Issue In HCV Protease Inhibitor Race
Schering-Plough’s Phase II boceprevir data are likely to fuel the debate.
PegIntron Increases Relapse-Free Survival In Stage III Melanoma, Schering Says
U.S. approval as adjuvant therapy for melanoma has been delayed by ODAC data requests, postponed meeting.